Impfstoffformulierung

Details

Veröffentlichungs-Nr.

EP4748392

Anmeldetag

20. November 2024

Veröffentlichung

27. Mai 2026

Rechtsraum

EP

IPC

A61K39/09, A61K9/00, C07K14/00

Abstract

The technology proposed herein concerns a vaccine formulation comprising a) an antigen comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of the N-terminal region of a first group B Streptococcus surface protein, and b) a buffer having a pH of 6 to 8 and comprising: a. aluminum hydroxide gel particles, and b. a buffer system comprising: i. phosphate, and optionally also a salt, or ii. histidine, and optionally also a sugar. The technology proposed herein further concerns a method of producing a vaccine formulation as well as a vaccine formulation for use in a method of reducing, preventing and/or treating a GBS infection.

Anmelder

Firma

MinervaX ApS

Land

🇩🇰 Dänemark